

Application No.: 10/810,649  
Amendment dated October 27, 2005  
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

### Remarks

Claims 1, 2, 6-10, 29, 30, 32 and 33 are now in the application. Claims 3-5, 11-28 and 31 which were directed to non elected inventions have been canceled without prejudice to their reentry at some later date. Claims 1 and 2 have been amended with respect to R by deleting the recitations related to “, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl”. Claims 1 and 2 have also been amended with respect to R<sub>1</sub> by deleting the recitations related to “a straight or branched C1-20 saturated or unsaturated aliphatic” and “an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic-substituted single or multi-ring aromatic; a single or multi-ring heterocyclic, a single or multi-ring heterocyclic-substituted aliphatic; an aliphatic-substituted aromatic”. These amendments have been made so that claims 1 and 2 remain directed to the elected invention.

Claims 1 and 2 have also been amended by deleting “xylene” for purposes of clarification and not to limit their scope. Claims 6, 30, 32 and 33 have been amended to recite the chemical names in place of referring to the figure for purposes of clarification and not to limit their scope. Claim 7 has been amended by deleting “useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable” for purposes of clarification and not to limit its scope.

Claims 1 and 2 were rejected under 35 U.S.C. 112, second paragraph as being indefinite in the recitation that the polyamine is a non-symmetrical xylene. This rejection has been overcome by deleting “xylene”.

Claim 7 was rejected under 35 U.S.C. 112, first and second paragraphs. These rejections have been overcome by deleting “useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable” from claim 7.

Application No.: 10/810,649  
Amendment dated October 27, 2005  
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2


The objections to claims 30, 32 and 33 as referring to a figure have been overcome.

In view of the above, reconsideration and allowance are, therefore, respectfully solicited.

In the event the Examiner believes an interview might serve to advance the prosecution of this application in any way, the undersigned attorney is available at the telephone number noted below.

The Director is authorized to charge any fees, or credit any overpayment associated with this communication, including any extension fees, to Deposit Account 22-0185.

Respectfully submitted,



Burton A. Amernick (24,852)  
Connolly Bove Lodge & Hutz LLP  
1990 M Street, N.W., Suite 800  
Washington, DC 20036-3425  
Telephone: 202-331-7111  
Telefax: 202-293-6229

Date: 10-27-05